Publications by authors named "Marco Basirico"

Claim this Profile
T
Trends in GVHD Epidemiology, Prophylaxis and Management: The Gruppo Italiano per il Trapianto di Midollo Osseo, Cellule Staminali Emopoietiche e Terapia Cellulare (GITMO) GVHD24 Study.
Nicola Polverelli, Caterina Zerbi, Maria Grazia Benevento, Mattia Algeri, Alessandra Algarotti

Am J Hematol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Doxycycline Restores Gemcitabine Sensitivity in Preclinical Models of Multidrug-Resistant Intrahepatic Cholangiocarcinoma.
Annamaria Massa, Francesca Vita, Caterina Peraldo-Neia, Chiara Varamo, Marco Basiricò

Cancers (Basel)· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Repurposing anti-mesothelin CAR-NK immunotherapy against colorectal cancer.
Erica Torchiaro, Marco Cortese, Consalvo Petti, Marco Basirico', Federica Invrea

J Transl Med· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Observational studies - The Cinderella of the Italian research system.
Celeste Cagnazzo, Marco Basiricò, Federica Palermo, Franca Fagioli

Tumori· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CSPG4 CAR-redirected Cytokine Induced Killer lymphocytes (CIK) as effective cellular immunotherapy for HLA class I defective melanoma.
Lidia Giraudo, Giulia Cattaneo, Loretta Gammaitoni, Ilenia Iaia, Chiara Donini

J Exp Clin Cancer Res· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Off-label and compassionate use of targeted anticancer therapies: The experience of an Italian pediatric cancer center.
Rosita Cenna, Marco Basiricò, Paola Berchialla, Nicoletta Bertorello, Celeste Cagnazzo

Pediatr Blood Cancer· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel Lymphocyte-Independent Antitumor Activity by PD-1 Blocking Antibody against PD-1+ Chemoresistant Lung Cancer Cells.
Ramona Rotolo, Valeria Leuci, Chiara Donini, Federica Galvagno, Annamaria Massa

Clin Cancer Res· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fluoropyrimidine‑induced cardiotoxicity in colorectal cancer patients: a prospective observational trial (CHECKPOINT).
Pasquale Lombardi, Giacomo Aimar, Caterina Peraldo-Neia, Alessandro Bonzano, Ilaria Depetris

Oncol Rep· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Case report: Preclinical efficacy of NEDD8 and proteasome inhibitors in patient-derived models of signet ring high-grade mucinous colorectal cancer from a Lynch syndrome patient.
Erica Torchiaro, Consalvo Petti, Sabrina Arena, Francesco Sassi, Giorgia Migliardi

Front Oncol· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Full chimaeric CAR.CIK from patients engrafted after allogeneic haematopoietic cell transplant: Feasibility, anti-leukaemic potential and alloreactivity across major human leukocyte antigen barriers.
Paola Circosta, Chiara Donini, Susanna Gallo, Lidia Giraudo, Loretta Gammaitoni

Br J Haematol· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Integrated Antitumor Activities of Cellular Immunotherapy with CIK Lymphocytes and Interferons against KIT/PDGFRA Wild Type GIST.
Erika Fiorino, Alessandra Merlini, Lorenzo D'Ambrosio, Ilaria Cerviere, Enrico Berrino

Int J Mol Sci· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Paclitaxel Restores Sensitivity to Chemotherapy in Preclinical Models of Multidrug-Resistant Intrahepatic Cholangiocarcinoma.
Annamaria Massa, Caterina Peraldo-Neia, Francesca Vita, Chiara Varamo, Marco Basiricò

Front Oncol· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PARP1 Inhibitor and Trabectedin Combination Does Not Increase Tumor Mutational Burden in Advanced Sarcomas-A Preclinical and Translational Study.
Ymera Pignochino, Giovanni Crisafulli, Giorgia Giordano, Alessandra Merlini, Enrico Berrino

Cancers (Basel)· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Novel Multidrug-Resistant Cell Line from an Italian Intrahepatic Cholangiocarcinoma Patient.
Caterina Peraldo-Neia, Annamaria Massa, Francesca Vita, Marco Basiricò, Chiara Raggi

Cancers (Basel)· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cytokine Profiling of End Stage Cancer Patients Treated with Immunotherapy.
Marco Carlo Merlano, Andrea Abbona, Matteo Paccagnella, Antonella Falletta, Cristina Granetto

Vaccines (Basel)· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CSPG4-Specific CAR.CIK Lymphocytes as a Novel Therapy for the Treatment of Multiple Soft-Tissue Sarcoma Histotypes.
Valeria Leuci, Chiara Donini, Giovanni Grignani, Ramona Rotolo, Giulia Mesiano

Clin Cancer Res· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pazopanib and Trametinib as a Synergistic Strategy against Osteosarcoma: Preclinical Activity and Molecular Insights.
Giulia Chiabotto, Giovanni Grignani, Maja Todorovic, Valentina Martin, Maria Laura Centomo

Cancers (Basel)· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Establishment and Characterization of a New Intrahepatic Cholangiocarcinoma Cell Line Resistant to Gemcitabine.
Chiara Varamo, Caterina Peraldo-Neia, Paola Ostano, Marco Basiricò, Chiara Raggi

Cancers (Basel)· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cytokine Induced Killer cells are effective against sarcoma cancer stem cells spared by chemotherapy and target therapy.
Giulia Mesiano, Giovanni Grignani, Erika Fiorino, Valeria Leuci, Ramona Rotolo

Oncoimmunology· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
BRAF and MEK Inhibitors Increase PD-1-Positive Melanoma Cells Leading to a Potential Lymphocyte-Independent Synergism with Anti-PD-1 Antibody.
Martina Sanlorenzo, Igor Vujic, Arianna Floris, Mauro Novelli, Loretta Gammaitoni

Clin Cancer Res· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PARP1 expression drives the synergistic antitumor activity of trabectedin and PARP1 inhibitors in sarcoma preclinical models.
Ymera Pignochino, Federica Capozzi, Lorenzo D'Ambrosio, Carmine Dell'Aglio, Marco Basiricò

Mol Cancer· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The combination of sorafenib and everolimus shows antitumor activity in preclinical models of malignant pleural mesothelioma.
Ymera Pignochino, Carmine Dell'Aglio, Simona Inghilleri, Michele Zorzetto, Marco Basiricò

BMC Cancer· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Combination of Sorafenib and Everolimus Abrogates mTORC1 and mTORC2 upregulation in osteosarcoma preclinical models.
Ymera Pignochino, Carmine Dell'Aglio, Marco Basiricò, Federica Capozzi, Marco Soster

Clin Cancer Res· April 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis